OncoMatch/Clinical Trials/NCT05174169
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Is NCT05174169 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies multiple treatments for stage iii colon cancer.
Treatment: Signatera test · mFOLFOX6 3-6 month · CAPOX 3 month · mFOLFIRINOX · mFOLFOX6 6 month · CAPOX 6 month — This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Disease stage
Required: Stage IIB, IIC, III
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: surgery — curative resection (R0)
en bloc complete gross resection of tumor (curative resection)
Cannot have received: systemic chemotherapy
Exception: one cycle of chemotherapy (5-FU or capecitabine with or without oxaliplatin) is allowed but not required after consent
Any prior systemic chemotherapy, targeted therapy, or immunotherapy; or radiation therapy administered as treatment for colorectal cancer
Cannot have received: targeted therapy
Any prior systemic chemotherapy, targeted therapy, or immunotherapy; or radiation therapy administered as treatment for colorectal cancer
Cannot have received: immunotherapy
Any prior systemic chemotherapy, targeted therapy, or immunotherapy; or radiation therapy administered as treatment for colorectal cancer
Cannot have received: radiation therapy
Any prior systemic chemotherapy, targeted therapy, or immunotherapy; or radiation therapy administered as treatment for colorectal cancer
Lab requirements
Blood counts
ANC >= 1500/mm3 (BEN: ANC < 1300/mm3 eligible); platelets >= 100,000/mm3; hemoglobin >= 9 g/dL
Kidney function
serum creatinine <= 1.5 x ULN or creatinine clearance >= 50 mL/min (Cockroft-Gault formula)
Liver function
total bilirubin <= ULN; alkaline phosphatase < 2.5 x ULN; AST and ALT < 2.5 x ULN
Cardiac function
NYHA class 2B or better
Adequate hematologic, hepatic, and renal function as defined; NYHA class 2B or better for cardiac function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Alabama at Birmingham Cancer Center · Birmingham, Alabama
- Thomas Hospital · Fairhope, Alabama
- Mobile Infirmary Medical Center · Mobile, Alabama
- University of South Alabama Mitchell Cancer Institute · Mobile, Alabama
- Kingman Regional Medical Center · Kingman, Arizona
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify